Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197737
Max Phase: Preclinical
Molecular Formula: C18H28N8O
Molecular Weight: 372.48
Associated Items:
ID: ALA5197737
Max Phase: Preclinical
Molecular Formula: C18H28N8O
Molecular Weight: 372.48
Associated Items:
Canonical SMILES: COc1ccccc1N1CCN(CCCCNc2nc(N)nc(N)n2)CC1
Standard InChI: InChI=1S/C18H28N8O/c1-27-15-7-3-2-6-14(15)26-12-10-25(11-13-26)9-5-4-8-21-18-23-16(19)22-17(20)24-18/h2-3,6-7H,4-5,8-13H2,1H3,(H5,19,20,21,22,23,24)
Standard InChI Key: IBPKFKZAYBVENB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 372.48 | Molecular Weight (Monoisotopic): 372.2386 | AlogP: 1.06 | #Rotatable Bonds: 8 |
Polar Surface Area: 118.45 | Molecular Species: BASE | HBA: 9 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.42 | CX LogP: 1.88 | CX LogD: -0.50 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.58 | Np Likeness Score: -1.49 |
1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J.. (2022) Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases., 227 [PMID:34710746] [10.1016/j.ejmech.2021.113931] |
Source(1):